Literature DB >> 1454314

Prevalence of glaucoma. The Beaver Dam Eye Study.

B E Klein1, R Klein, W E Sponsel, T Franke, L B Cantor, J Martone, M J Menage.   

Abstract

PURPOSE: The purpose of this study is to determine the prevalence of glaucoma in the population participating in the Beaver Dam Eye Study (n = 4926).
METHODS: All subjects were examined according to standard protocols, which included applanation tonometry, examination of the anterior chamber, perimetry, grading of fundus photographs of the optic disc, and a medical history interview. Visual field, cup-to-disc ratio, and intraocular pressure (IOP) criteria were used to define the presence of open-angle glaucoma. Definite open-angle glaucoma was defined by the presence of any two or all three of the following: abnormal visual field, large or asymmetric cup-to-disc ratio, high IOP.
RESULTS: The overall prevalence of definite open-angle glaucoma was 2.1%. The prevalence increased with age from 0.9% in people 43 to 54 years of age to 4.7% in people 75 years of age or older. There was no significant effect of sex after adjusting for age. Of the 104 cases of definite open-angle glaucoma, 33 had IOPs less than 22 mmHg in the involved eye. Hemorrhage on the optic disc was found in 46 people; 2 of these had glaucoma. Narrow-angle glaucoma was rare, with two definite cases in the population.
CONCLUSION: The prevalence of open-angle glaucoma in Beaver Dam is similar to that in other white populations. Findings from this study re-emphasize the notion that estimates of glaucoma prevalence should be based on assessing multiple risk indicators.

Entities:  

Mesh:

Year:  1992        PMID: 1454314     DOI: 10.1016/s0161-6420(92)31774-9

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  245 in total

Review 1.  Nitric-oxide synthase and neurodegeneration/neuroprotection.

Authors:  P L Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

Review 2.  Should diabetic patients be screened for glaucoma? DARTS/MEMO Collaboration.

Authors:  J D Ellis; A D Morris; C J MacEwen
Journal:  Br J Ophthalmol       Date:  1999-03       Impact factor: 4.638

3.  The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care.

Authors:  D N Bateman; R Clark; A Azuara-Blanco; M Bain; J Forrest
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

Review 4.  A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma.

Authors:  N N Osborne; J Melena; G Chidlow; J P Wood
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

5.  Purchasing good quality eye care: the provider's view.

Authors:  G Vafidis
Journal:  Qual Health Care       Date:  1997-06

6.  Glaucoma: our role in reducing the burden of blindness.

Authors:  Lenworth N Johnson
Journal:  J Natl Med Assoc       Date:  2002-10       Impact factor: 1.798

7.  The utilization of eye care services by persons with glaucoma in rural south India.

Authors:  Alan L Robin; Praveen K Nirmalan; Ramasamy Krishnadas; Rengappa Ramakrishnan; Joanne Katz; James Tielsch; Ravilla D Thulasiraj; David S Friedman
Journal:  Trans Am Ophthalmol Soc       Date:  2004

8.  Results of the betaxolol versus placebo treatment trial in ocular hypertension.

Authors:  Deborah Kamal; David Garway-Heath; Simon Ruben; Fiona O'Sullivan; Catey Bunce; Anath Viswanathan; Wendy Franks; Roger Hitchings
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-19       Impact factor: 3.117

9.  Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino Eye Study.

Authors:  Vikas Chopra; Rohit Varma; Brian A Francis; Joanne Wu; Mina Torres; Stanley P Azen
Journal:  Ophthalmology       Date:  2007-08-22       Impact factor: 12.079

10.  Differential up-regulation of Vesl-1/Homer 1 protein isoforms associated with decline in visual performance in a preclinical glaucoma model.

Authors:  Simon Kaja; Yuliya Naumchuk; Stephanie L Grillo; Priscilla K Borden; Peter Koulen
Journal:  Vision Res       Date:  2013-11-09       Impact factor: 1.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.